Latest Period
Q2 2026
Security Snapshot
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) Institutional Ownership
CUSIP: 22663K107
13F Institutional Holders and Ownership History from Q3 2018 to Q2 2026
Institutions Reporting
260
Shares (Excl. Options)
123,542,838
Price
$37.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CRNX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 123,542,838
- Total 13F value
- $4,621,967,235
- Portfolio coverage rank
- 0%
- Share change
- +833,549
- Value change
- +$38,219,119
- Number of holders
- 260
- Shares outstanding
- 104,868,882
- SEC-reported price per share
- $83.90
- Insider filing price
- $83.90
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 22663K107.
- 260 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 241 to 260 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $4,457,218,533 to $4,621,967,235.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 260 institutions filings for Q2 2026.
Security key
22663K107
Latest holder period
Q2 2026
13F holders
260
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
CRNX full holder history
Crinetics Pharmaceuticals, Inc. SEC filings
Crinetics Pharmaceuticals, Inc. company facts
Crinetics Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22663K107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
CRNX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 8.5% | $752,117,830 | 8,989,098 | Farallon Capital Management, L.L.C. | 30 Jun 2026 | |||
| Farallon Capital Partners, L.P. | 8.5% | +42% | $373,521,762 | +$111,673,450 | 8,024,098 | +43% | Dapice Joshua J. | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.8% | -12% | $596,657,798 | -$85,855,460 | 7,131,084 | -13% | Wellington Management Group LLP | 30 Jun 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.1% | $252,255,164 | 6,395,922 | DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $197,604,263 | 5,440,646 | Vanguard Capital Management | 31 Mar 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.1% | $211,201,634 | 5,355,011 | T. Rowe Price Associates, Inc. | 31 Mar 2026 | |||
| FMR LLC | 1.4% | -91% | $120,475,670 | -$1,047,329,017 | 1,439,891 | -90% | FMR LLC | 31 Jul 2026 |
As of 30 Jun 2026, 260 institutional investors reported holding 123,542,838 shares of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX). This represents 118% of the company’s total 104,868,882 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
94%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 15,840,219 | +0.51% | 0.03% | $592,740,991 |
| BlackRock, Inc. | 9.3% | 9,758,938 | +15% | 0.01% | $365,179,474 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 8.6% | 8,989,098 | +7.8% | 2% | $336,372,047 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.8% | 7,131,084 | -13% | 0.05% | $266,845,165 |
| Driehaus Capital Management LLC | 6.2% | 6,463,551 | +1.1% | 1.4% | $241,866,078 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.9% | 6,212,681 | +16% | 0.02% | $232,480,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.6% | 4,832,614 | +4.2% | 0.01% | $180,836,416 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 4,745,262 | +1.5% | 0% | $177,567,704 |
| Jupiter Topco LLC | 4.3% | 4,557,689 | 0% | 0.07% | $170,509,459 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 2,727,633 | +10% | 0.01% | $102,088,876 |
| STATE STREET CORP | 2.6% | 2,689,350 | +12% | 0% | $100,635,477 |
| Bellevue Group AG | 2.5% | 2,620,000 | -20% | 2.1% | $98,040,400 |
| BAKER BROS. ADVISORS LP | 2.2% | 2,351,465 | 0% | 0.44% | $87,991,820 |
| Polar Capital Holdings Plc | 2.2% | 2,274,411 | 0.24% | $85,108,460 | |
| Pictet Asset Management Holding SA | 2% | 2,075,375 | +10% | 0.07% | $77,572,984 |
| T. Rowe Price Investment Management, Inc. | 1.9% | 2,010,288 | +3.6% | 0.05% | $75,225,000 |
| GW&K Investment Management, LLC | 1.7% | 1,731,140 | +6.9% | 0.51% | $64,780,000 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.6% | 1,678,490 | -2.2% | 0.06% | $62,809,096 |
| Siren, L.L.C. | 1.4% | 1,420,788 | -25% | 1.1% | $53,165,887 |
| JPMORGAN CHASE & CO | 1.3% | 1,365,030 | +3% | 0% | $50,602,923 |
| First Light Asset Management, LLC | 1.3% | 1,360,866 | +25% | 3.1% | $50,923,606 |
| MORGAN STANLEY | 1.3% | 1,338,531 | +46% | 0% | $50,087,876 |
| BANK OF AMERICA CORP /DE/ | 1.3% | 1,333,071 | +86% | 0% | $49,883,517 |
| NOVO HOLDINGS A/S | 1.3% | 1,320,000 | -15% | 2.9% | $49,394,400 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 1,270,531 | +49% | 0.01% | $47,539,171 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
32
Latest
Q2 2026
Rows shown
1-25 of 32
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 123,542,838 | $4,621,967,235 | +$38,219,119 | $37.42 | 260 |
| 2026 Q1 | 122,775,162 | $4,457,218,533 | +$303,483,388 | $36.32 | 241 |
| 2025 Q4 | 111,610,722 | $5,195,629,181 | +$186,370,978 | $46.55 | 240 |
| 2025 Q3 | 107,709,232 | $4,486,288,734 | +$149,976,766 | $41.65 | 225 |
| 2025 Q2 | 104,559,713 | $3,007,383,972 | +$75,026,414 | $28.76 | 220 |
| 2025 Q1 | 101,790,412 | $3,418,305,905 | +$9,856,311 | $33.54 | 225 |
| 2024 Q4 | 99,690,161 | $5,097,004,672 | +$758,098,969 | $51.13 | 245 |
| 2024 Q3 | 84,525,573 | $4,321,960,073 | +$33,724,194 | $51.10 | 233 |
| 2024 Q2 | 82,487,807 | $3,694,594,767 | +$92,152,096 | $44.79 | 232 |
| 2024 Q1 | 80,384,076 | $3,762,661,947 | +$486,785,470 | $46.81 | 201 |
| 2023 Q4 | 70,656,199 | $2,513,959,167 | +$68,274,571 | $35.58 | 180 |
| 2023 Q3 | 68,535,017 | $2,038,114,354 | +$440,832,585 | $29.74 | 171 |
| 2023 Q2 | 54,057,835 | $974,084,774 | -$11,795,159 | $18.02 | 138 |
| 2023 Q1 | 55,062,782 | $884,310,368 | +$2,280,401 | $16.06 | 127 |
| 2022 Q4 | 54,817,398 | $1,003,122,430 | -$14,306,281 | $18.30 | 121 |
| 2022 Q3 | 51,456,378 | $1,010,816,996 | +$16,147,822 | $19.64 | 118 |
| 2022 Q2 | 50,645,843 | $944,532,132 | +$94,595,270 | $18.65 | 109 |
| 2022 Q1 | 45,482,453 | $997,426,956 | -$15,117,112 | $21.95 | 114 |
| 2021 Q4 | 44,273,322 | $1,256,550,441 | +$251,517,738 | $28.41 | 114 |
| 2021 Q3 | 33,632,624 | $708,150,662 | +$17,177,215 | $21.05 | 91 |
| 2021 Q2 | 32,726,853 | $616,933,642 | +$42,446,903 | $18.85 | 81 |
| 2021 Q1 | 30,730,499 | $465,273,247 | +$5,520,857 | $15.28 | 78 |
| 2020 Q4 | 30,426,213 | $429,299,885 | -$4,592,533 | $14.11 | 84 |
| 2020 Q3 | 30,337,604 | $475,397,972 | -$19,900,117 | $15.67 | 70 |
| 2020 Q2 | 31,451,376 | $546,085,663 | +$188,712,886 | $17.52 | 79 |